Senti Biosciences (SNTI) News Today $1.52 -0.01 (-0.65%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.56 +0.04 (+2.89%) As of 08/15/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNTI Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Chardan Capital Issues Optimistic Forecast for SNTI EarningsAugust 15 at 2:52 AM | americanbankingnews.comSenti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechAugust 14 at 9:15 AM | globenewswire.comSenti Biosciences Discusses Phase 2 Dose Selection for SENTI-202 in Virtual Investor SegmentAugust 12, 2025 | quiverquant.comQSenti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid LeukemiaAugust 12, 2025 | globenewswire.comSenti Biosciences' (SNTI) Buy Rating Reiterated at Chardan CapitalAugust 11, 2025 | americanbankingnews.comSenti Biosciences, Inc.: Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML ...August 8, 2025 | finanznachrichten.deSenti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025August 7, 2025 | globenewswire.comSenti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid LeukemiaAugust 5, 2025 | globenewswire.comSenti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 23, 2025 | finance.yahoo.comSenti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | globenewswire.comSenti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience ForumJuly 21, 2025 | globenewswire.comSenti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of DirectorsJuly 18, 2025 | globenewswire.comSenti Biosciences (NASDAQ:SNTI) Upgraded by Wall Street Zen to "Sell" RatingJuly 12, 2025 | marketbeat.comSenti Biosciences (NASDAQ:SNTI) Trading Up 2.5% - Here's What HappenedJuly 4, 2025 | marketbeat.comNASDAQ:SNTI Financials | Senti Biosciences Inc - Investing.comJuly 3, 2025 | investing.comSNTI - Senti Biosciences Inc Sustainability - MorningstarJuly 2, 2025 | morningstar.comMSenti Bio Participates in Nasdaq Amplify Spotlight SeriesJune 30, 2025 | globenewswire.comSenti Biosciences, Inc. to Present at 2025 SEED Conference on Tumor-Specific Therapies - NasdaqJune 26, 2025 | nasdaq.comSenti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) ConferenceJune 24, 2025 | globenewswire.comSenti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid LeukemiaJune 18, 2025 | globenewswire.comChardan Capital Reaffirms "Buy" Rating for Senti Biosciences (NASDAQ:SNTI)June 12, 2025 | marketbeat.comSenti Biosciences Announces New Employment Inducement GrantsJune 9, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIJune 7, 2025 | prnewswire.comLaidlaw & Co. Initiates Coverage of Senti Biosciences (SNTI) with Buy RecommendationJune 7, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIJune 6, 2025 | globenewswire.comSenti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLCJune 6, 2025 | globenewswire.comSenti Biosciences (NASDAQ:SNTI) Coverage Initiated at LaidlawJune 6, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIJune 2, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIJune 1, 2025 | prnewswire.comSenti Biosciences, Inc. (NASDAQ:SNTI) Short Interest UpdateJune 1, 2025 | marketbeat.comSenti Biosciences (NASDAQ:SNTI) Stock Price Down 3% - Time to Sell?May 30, 2025 | marketbeat.comSenti Biosciences Receives Additional $1 Million from CIRM to Support Clinical Development of SENTI-202 Cell TherapyMay 23, 2025 | nasdaq.comSenti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment WebinarMay 22, 2025 | globenewswire.comSenti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202May 22, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIMay 20, 2025 | prnewswire.comSNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law FirmMay 20, 2025 | prnewswire.comSNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law FirmMay 15, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIMay 13, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIMay 12, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIMay 9, 2025 | globenewswire.comSenti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202May 8, 2025 | globenewswire.comSenti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical DevelopmentMay 6, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIMay 6, 2025 | prnewswire.comSenti Biosciences (SNTI) to Release Earnings on ThursdayMay 5, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTIMay 5, 2025 | globenewswire.comSenti Biosciences (NASDAQ:SNTI) Receives Buy Rating from Chardan CapitalMay 4, 2025 | marketbeat.comSenti Biosciences Announces Positive Data for SENTI-202 in Phase 1 Trial at AACR Annual Meeting 2025May 3, 2025 | nasdaq.comSenti Bio Releases Virtual Investor "What This Means" SegmentMay 2, 2025 | tmcnet.comSenti Bio Releases Virtual Investor “What This Means” SegmentMay 1, 2025 | globenewswire.comSenti Bio to Present at the Citizens JMP Life Sciences ConferenceApril 30, 2025 | globenewswire.com Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address SNTI Media Mentions By Week SNTI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNTI News Sentiment▼0.690.62▲Average Medical News Sentiment SNTI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNTI Articles This Week▼102▲SNTI Articles Average Week Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SELLAS Life Sciences Group News FitLife Brands News MEI Pharma News Lexeo Therapeutics News Theratechnologies News Cellectis News Enanta Pharmaceuticals News Korro Bio News Molecular Partners News BioHarvest Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNTI) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access